Skip to main content
    P

    Puma Biotechnology Inc (PBYI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $10.52
    +0.32 (+3.14%)

    Market Cap: $526.52M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    79%(31/39)
    Avg Surprise
    +54.55%
    Streak
    10 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.12
    Range$0.12 - $0.12
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.19-36.8%
    60d ago$0.19-36.8%
    30d ago$0.19-36.8%
    7d ago$0.19-36.8%
    Current$0.12
    Revenue Consensus
    $58M
    Range$58M - $58M
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.49
    Range$0.49 - $0.49
    1 analysts
    Revenue Consensus
    $-152500000
    Range$-152500000 - $-152500000
    0 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.49---
    Sep 26EST
    		-$0.12---
    Jun 26
    Reported Aug 6
    		$0.16$0.06+166.67%Beat+33.3%
    Mar 26
    Reported May 7
    		$-0.04N/A+69.23%Beat-166.7%
    Dec 25
    Reported Feb 26
    		$0.26$0.19+36.84%Beat-39.5%
    Sep 25
    Reported Nov 6
    		$0.21$0.09+133.33%Beat-53.3%
    Jun 25
    Reported Aug 7
    		$0.12$0.08+50.00%Beat+340.0%
    Mar 25
    Reported May 8
    		$0.06$-0.02+400.00%Beat+220.0%
    Dec 24
    Reported Feb 27
    		$0.43$0.14+207.14%Beat+65.4%
    Sep 24
    Reported Nov 7
    		$0.45$0.38+18.42%Beat+164.7%
    Jun 24
    Reported Aug 1
    		$-0.05$-0.10+50.00%Beat-150.0%
    Mar 24
    Reported May 2
    		$-0.05N/A+66.67%Beat-155.6%
    Dec 23
    Reported Feb 29
    		$0.26$0.30-13.33%Miss+316.7%
    Sep 23
    Reported Nov 2
    		$0.17$0.14+21.43%Beat+240.0%
    Jun 23
    Reported Aug 3
    		$0.10$0.07+42.86%Beat-64.3%
    Mar 23
    Reported May 4
    		$0.09$-0.01+1000.00%Beat+1000.0%
    Dec 22
    Reported Mar 2
    		$-0.12$0.01-1300.00%Miss-220.0%
    Sep 22
    Reported Nov 3
    		$0.05$0.03+66.67%Beat+105.1%
    Jun 22
    Reported Aug 4
    		$0.28$0.09+211.11%Beat-12.5%
    Mar 22
    Reported May 5
    		$-0.01N/A+90.91%Beat-101.8%
    Dec 21
    Reported Mar 3
    		$0.10$-0.09+211.11%Beat+126.3%
    Sep 21
    Reported Nov 4
    		$-0.99$-0.22-350.00%Miss-65.0%
    Jun 21
    Reported Aug 5
    		$0.32$-0.14+328.57%Beat-8.6%
    Mar 21
    Reported May 6
    		$0.55$0.34+61.76%Beat+375.0%
    Dec 20
    Reported Feb 25
    		$-0.38$-0.31-22.58%Miss-3900.0%
    Sep 20
    Reported Nov 5
    		$-0.60$-0.14-328.57%Miss-400.0%
    Jun 20
    Reported Aug 6
    		$0.35$0.14+150.00%Beat+161.4%
    Mar 20
    Reported May 7
    		$-0.20N/A+70.59%Beat-200.0%
    Dec 19
    Reported Feb 20
    		$0.01N/A+103.85%Beat+101.3%
    Sep 19
    Reported Nov 6
    		$-0.12N/A+73.33%Beat-175.0%
    Jun 19
    Reported Aug 8
    		$-0.57$-0.89+35.96%Beat+3.4%
    Mar 19
    Reported May 9
    		$0.20$-0.20+200.00%Beat+900.0%
    Dec 18
    Reported Feb 28
    		$-0.80$-0.77-3.90%Miss+53.2%
    Sep 18
    Reported Nov 1
    		$0.16N/A+135.56%Beat+111.8%
    Jun 18
    Reported Aug 9
    		$-0.59$-0.82+28.05%Beat+57.2%
    Mar 18
    Reported May 9
    		$0.02N/A+106.45%Beat+101.7%
    Dec 17
    Reported Mar 1
    		$-1.71$-1.97+13.20%Beat+16.2%
    Sep 17
    Reported Nov 9
    		$-1.36$-1.42+4.23%Beat-
    Jun 17
    Reported Aug 9
    		$-1.38$-1.31-5.34%Miss-
    Mar 17
    Reported May 10
    		$-1.16$-1.20+3.33%Beat-
    Dec 16
    Reported Mar 1
    		$-2.04$-1.92-6.25%Miss-

    Key Metrics

    Valuation
    P/E Ratio17.83EV/EBITDA12.09x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin11.60%Operating Margin13.40%
    ROE22.00%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage8.76x
    Current Ratio2.91xQuick Ratio2.64x
    Trading Statistics
    Beta1.21Avg Volume331.13K
    52-Week High$10.5052-Week Low$4.58

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$9.99
    SMA 20$9.86
    SMA 50$9.42
    SMA 200$7.66
    EMA 10$10.09
    EMA 20$9.88
    EMA 50$9.40
    EMA 200$7.78

    MACD

    Line: 0.27Signal: 0.22Hist: 0.04

    ADX

    ADX: 12.3+DI: 22.2-DI: 14.8

    Aroon & PSAR

    Aroon Up100.0
    Aroon DownN/A
    PSAR$9.62

    Bollinger Bands

    Upper Band$10.47
    Lower Band$9.24
    %B Position1247%(Upper)
    Band Width1.04

    RSI (14-Day)

    Neutral
    66.0

    Momentum Oscillators

    Stoch %K78.5
    Stoch %D80.7
    Williams %R-13.8
    ROC (10d)6.9%
    Momentum0.68
    CCI (20d)186.8
    MFI (14d)56.0

    Volatility Measures

    ATR (14d)$0.41(3.9%)
    StdDev (20d)0.31
    Hist Vol40.4%(High)

    Volume Flow

    VWAP$10.50
    OBV29.1M
    AD Line14.7M
    CMF (20d)-0.013

    Volume Metrics

    Avg Vol (20d)344.5K
    Vol Ratio1.1x
    VWMA (20d)$9.84

    Pivot Points

    R3$10.81
    R2$10.62
    R1$10.41
    Pivot Point$10.22
    S1$10.01
    S2$9.82
    S3$9.61

    Advanced Oscillators

    TSI20.98
    Ultimate Osc58.5
    KST70.10

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$56.50M$44.81M$75.45M$54.48M$52.44M$46.01M$59.08M$80.54M$47.08M$43.77M$72.18M$56.12M
    Cost of Revenue$12.47M$10.42M$23.13M$12.17M$12.30M$10.56M$13.92M$29.10M$10.66M$10.73M$24.32M$13.28M
    Gross Profit$44.03M$34.39M$52.33M$42.30M$40.13M$35.45M$45.16M$51.45M$36.42M$33.04M$47.85M$42.83M
    Operating Expenses$36.44M$38.22M$35.22M$32.73M$33.50M$31.47M$31.79M$29.37M$38.60M$35.34M$33.06M$34.25M
    R&D$18.89M$19.80M$16.84M$15.91M$15.45M$13.86M$15.17M$12.55M$13.63M$13.59M$12.87M$11.45M
    SG&A$17.55M$18.42M$18.38M$16.82M$18.05M$17.60M$16.62M$16.82M$24.97M$21.75M$20.18M$22.80M
    Operating Income$7.58M$-3,828,000$17.11M$9.57M$6.64M$3.98M$13.37M$22.08M$-2,179,000$-2,299,000$14.80M$8.59M
    Interest Income$831,000$1.00M$977,000$1.04M$956,000$1.10M$1.23M$1.28M$1.24M$972,000$719,000$689,000
    Interest Expense$180,000$731,000$1.12M$1.49M$1.84M$2.18M$2.62M$3.10M$3.37M$3.36M$3.35M$3.34M
    Income Before Tax$8.24M$-3,427,000$17.11M$9.24M$6.17M$3.27M$12.24M$20.61M$-4,151,000$-4,595,000$12.80M$6.01M
    Income Tax Expense$56,000$326,000$3.67M$399,000$310,000$293,000$-7,067,000$291,000$378,000$220,000$536,000$213,000
    Net Income$8.19M$-3,753,000$13.44M$8.84M$5.86M$2.97M$19.30M$20.32M$-4,529,000$-4,815,000$12.27M$5.80M
    EBITDA$10.11M$-1,114,000$19.91M$12.41M$9.81M$7.14M$16.47M$25.30M$885,000$689,000$18.33M$11.54M
    EBIT$7.59M$-3,698,000$17.25M$9.69M$7.05M$4.34M$13.63M$22.43M$-2,023,000$-2,208,000$15.44M$8.66M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PBYI

    News

    Puma Biotechnology grants shares. TD Cowen targets Puma Biotechnology stock at USD 6.00

    Puma Biotechnology granted 7,500 shares to a new non-executive employee and received an updated price target of $6.00 from TD Cowen, up from $5.00. The company reported second-quarter revenue of $56.50 million...

    ad-hoc-news.de•10/13/26•Somewhat-Bullish

    Puma Biotechnology Reports Q2 2026 Results: Full Earnings Call Transcript

    Puma Biotechnology reported Q2 2026 total revenue of $56.5 million, with NERLYNX net product revenue reaching $53.6 million. The company has raised its full-year 2026 guidance for NERLYNX product revenue to $205-$209...

    Benzinga•10/12/26•Bullish

    how InvestingPro’s fair value caught Puma Biotech’s 95% surge By Investing.com

    InvestingPro's Fair Value models identified Puma Biotechnology (NASDAQ:PBYI) as significantly undervalued in November 2025 at $4.73 per share. Since then, the stock has surged 95% to $9.97 by October 2026...

    Investing.com•10/9/26•Bullish

    Puma Biotechnology stock fell 1.76 percent after award news

    Puma Biotechnology's stock fell 1.76% to USD 9.50 on October 6, 2026, despite strong Q2 2026 earnings that beat consensus. The company recently granted 7,500 inducement shares to a new employee and is advancing its...

    AD HOC NEWS•10/6/26•Neutral

    Form 13D/A Puma Biotechnology For: 6 October By Investing.com

    This article reports on a Form 13D/A filing for Puma Biotechnology (PBYI) for October 6th. The filing indicates a significant disclosure related to ownership in the company. Puma Biotechnology's stock experienced a 3.21%...

    Investing.com UK•10/6/26•Neutral

    PBYI Valuation and Fair Value

    P/E
    17.8x
    Forward P/E
    3.5x
    EV/EBITDA
    12.1x
    PEG
    0.0x
    P/B
    3.9x
    See GNG's fair value

    PBYI Profitability: Margins, ROIC and FCF

    Gross margin
    74.8%
    Operating margin
    13.4%
    Net margin
    11.6%
    ROE
    22.0%
    FCF margin
    17.8%

    PBYI Competitors

    CompanyTicker
    Shattuck Labs IncSTTK
    Evolent Health IncEVH
    Bright Minds Biosciences IncDRUG
    Oncology Institute IncTOI
    ZimVie IncZIMV
    Delcath Systems IncDCTH
    Valneva SE ADRVALN
    CytomX Therapeutics IncCTMX

    Sector: Healthcare

    PBYI Bull Case vs Bear Case

    Bull case

    • PBYI converts 17.8% of revenue into free cash flow.
    • PBYI beat EPS estimates in 100.0% of its last 8 reported quarters.

    PBYI Earnings: Beat Rate and Next Report

    Beat rate
    8 of 8 quarters (100.0%)
    Average surprise
    135.2%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.12
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About PBYI

    Does PBYI pay dividends?

    Puma Biotechnology Inc (PBYI) does not currently pay a regular dividend.

    What is PBYI's P/E ratio?

    Puma Biotechnology Inc has a price-to-earnings (P/E) ratio of 17.83.

    What is PBYI's market cap?

    Puma Biotechnology Inc (PBYI) has a market capitalization of $526.52M with a current stock price of $10.52.

    Related stocks

    Sector: Healthcare

    All stocks starting with P

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In